Abstract 435TiP
Background
Treatment with PD-L1 or PD-1 targeting antibodies is a cornerstone in cancer therapy, but not all patients benefit from these drugs. For most indications, the current reference biomarker is PD-L1 expression in a tumor biopsy, but this method has several disadvantages. Molecular imaging, such as PET/CT using receptor-specific radiotracers, offers non-invasive, real-time visualization of treatment targets. Previous trials have explored a few PD-L1/PD-1 radiotracers but lacked a systematic approach focused on a single tumor type and standardized clinical management.
Trial design
The MIMIR-trial (EU CT 2022-500808-21-00, NCT05742269) involves newly diagnosed mTNBC patients planned for first-line systemic treatment. Participants undergo a PD-L1 PET/CT scan with [89Zr]Zr-atezolizumab followed by a biopsy, with results guiding subsequent treatment with chemotherapy (carboplatin and nab-paclitaxel), combined with atezolizumab based on PD-L1 status as determined by IHC and/or PET. Treatment effectiveness is assessed bi-monthly, and therapy is continued until disease progression or unmanageable toxicity. The primary aim is to determine the statistical concordance (Cohen’s kappa coefficient) between PD-L1 status by PET and IHC. To target a kappa of 0.80 with a precision of +/- 0.15, 64 patients are required in this study. Secondary objectives include evaluating the predictive value of PD-L1 PET for treatment response and development of immunotherapy-mediated toxicity. Tissue, feces, and blood samples are collected for further translational analysis. The trial is ongoing at Karolinska University Hospital in Stockholm, Sweden, with three patients enrolled so far. An additional cohort of patients with non small cell lung cancer will be opened during Q3-4 2024.
Clinical trial identification
EU CT 2022-500808-21-00, NCT05742269.
Editorial acknowledgement
Legal entity responsible for the study
Karolinska University hospital, Region Stockholm, Sweden.
Funding
Roche Sweden AB.
Disclosure
J. Bergh: Non-Financial Interests, Personal, Advisory Board: stratipath. All other authors have declared no conflicts of interest.
Resources from the same session
533P - First-line treatment in older patients with metastatic colorectal cancer: A large real-world study
Presenter: debora basile
Session: Poster session 15
534P - Second-line treatment in older patients with metastatic colorectal cancer: The ELECTRA study
Presenter: Alessia Cordua
Session: Poster session 15
535P - Safety and efficacy of first-line immune checkpoint inhibitors in elderly colorectal cancer patients: An Italian real-world multicenter experience
Presenter: Alessandra Boccaccino
Session: Poster session 15
536P - A randomized phase II/III trial comparing hepatectomy followed by mFOLFOX6 with hepatectomy alone for liver metastasis from colorectal cancer: Long-term results of JCOG0603
Presenter: Yukihide Kanemitsu
Session: Poster session 15
537P - Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Updated findings from a single-arm, prospective phase II trial (RIFLE)
Presenter: Yajiie Chen
Session: Poster session 15
538P - Combined hepatectomy with complete cytoreduction (CCS) and hyperthermic intraperitoneal chemotherapy (HIPEC) vs. HIPEC alone for metastatic colorectal cancer: A systematic review and meta-analysis
Presenter: Gabriele Lech
Session: Poster session 15
540P - Early treatment discontinuation (ETD) in dMMR/MSI-H metastastic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICIs)
Presenter: Julien Taieb
Session: Poster session 15
541P - Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Subgroup efficacy and expanded safety analyses from CheckMate 8HW
Presenter: Thierry André
Session: Poster session 15